Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Exact Sciences rejects acquisition proposal from Sequenom
The board, after reviewing the proposal with its financial and legal advisors, has determined to reject the proposal. The company is actively pursuing a strategic alternative that the
The board, after reviewing the proposal with its financial and legal advisors, has determined to reject the proposal. The company is actively pursuing a strategic alternative that the
From September 2001 to November 2008, Dr Llana held various positions of increasing responsibility at Biogen Idec, including most recently as the vice president of its oncology/rheumatology strategic
The financing round will support the commercialization of Singulex technologies in the diagnostics market. As part of the financing, Hironori Hozoji, investment officer for Jafco Life Science Investment,
“We made great progress during 2008 in a number of areas,” said chief executive officer Henri A. Termeer. “We delivered strong financial results, continued to grow our existing
Edward Richmond, formerly the executive vice president of operations, will assume the new position of executive vice president of customer solutions focusing on global customer service, program management,
The company has granted the underwriter of the offering a 45-day option to purchase up to an additional 457,500 units to cover over-allotments, if any. Net proceeds of
Niravam (alprazolam orally disintegrating tablets), Parcopa (carbidopa-levodopa orally disintegrating tablets) and Kemstro (baclofen orally disintegrating tablets) are central nervous system (CNS) products. Niravam and Parcopa have been commercially
The consortium, consisting of a total of 16 companies and research institutions from 11 countries. The project has been set up to standardize the pre-analytical handling of patient
“We’re extremely proud and fortunate to have Rusty join our team,” said Page Erickson, chairman of the board of directors. “As Celerus continues to grow and achieve profitability,
Acclarent intends to use the proceeds to continue commercialization of its Balloon Sinuplasty technology, as well as on-going investment in product development and clinical studies. Johnson & Johnson